GeNeuro and Servier Sign Partnership to Develop First Medicine Addressing a Causal Factor of Multiple Sclerosis

PRESS RELEASE

December 2, 2014, Geneva, Switzerland, and Suresnes, France - GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has entered into a strategic partnership with Servier, the leading independent French pharmaceutical company, to develop and market GNbAC1 in Multiple Sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

Silahkan klik di sini untuk informasi lebih detail.

 

For more information, please contact :

Francois Curtin, CEO
GeNeuro
Tel : +41 (0)22 794 50 85
Mike Sinclair
Halsin Partners
Tel : +44 (0)20 73182955
Email : msinclair@halsin.com                             
 
Direction de la Communication Institutionnelle
SERVIER
Phone : +33 (0)1 55 72 60 37